Effective
therapies for
stroke are still limited due to its complex pathological manifestations.
QiShenYiQi (QSYQ), a component-based Chinese medicine capable of reducing organ injury caused by
ischemia/reperfusion, may offer an alternative option for
stroke treatment and post-
stroke recovery. Recently, we reported a beneficial effect of QSYQ for
acute stroke via modulation of the neuroinflammatory response. However, if QSYQ plays a role in subacute
stroke remains unknown. The pharmacological action of QSYQ was investigated in experimental
stroke rats which underwent 90 min
ischemia and 8 days reperfusion in this study. Neurological and locomotive deficits,
cerebral infarction,
brain edema, and BBB integrity were assessed. TMT-based quantitative proteomics were performed to identify differentially expressed
proteins following QSYQ treatment. Immunohistochemistry, western blot analysis, RT-qPCR, and ELISA were used to validate the proteomics data and to reveal the action mechanisms. Therapeutically, treatment with QSYQ (600 mg/kg) for 7 days significantly improved neurological recovery, attenuated
infarct volume and
brain edema, and alleviated BBB breakdown in the
stroke rats. Bioinformatics analysis indicated that
protein galectin-3 and its mediated inflammatory response was closely related to the beneficial effect of QSYQ. Specially, QSYQ (600 mg/kg) markedly downregulated the
mRNA and
protein expression levels of
galectin-3, TNF-α, and
IL-6 in CI/RI brain as well as serum levels of TNF-α and
IL-6. Overall, our findings showed that the effective action of QSYQ against the subacute phase of CI/RI occurs partly via regulating
galectin-3 mediated inflammatory reaction.